Novartis gains another potential MS growth engine after remibrutinib beats teriflunomide in two Phase III trials

Novartis has strengthened its long-term multiple sclerosis growth strategy after remibrutinib succeeded in two separate Phase III trials, clearing a major clinical hurdle for a potential high-efficacy oral treatment in relapsing disease. The dual REMODEL-1 and REMODEL-2 victories give the pharmaceutical group an opportunity to complement its rapidly growing Kesimpta franchise with a treatment offering a very different administration profile, potentially widening its reach across patient preferences. Investors responded strongly, with Novartis shares rising roughly 6% as the market assigned greater value to a program that could develop into another multibillion-dollar growth asset. The company plans global regulatory submissions after detailed results are presented at MSToronto2026, shifting attention toward whether remibrutinib can distinguish itself in an increasingly competitive Bruton’s tyrosine kinase inhibitor field. Importantly, Novartis reported no liver safety signal across the pivotal trials, a finding that could become commercially significant given safety concerns that have affected other therapies in the class.

The topline announcement does not yet reveal exactly how much remibrutinib reduced annualized relapse rates compared with teriflunomide, limiting direct comparisons with rival programs until the full dataset becomes available. Both pivotal trials nevertheless met their primary endpoint independently and showed superiority across key secondary endpoints, including inflammatory brain lesions measured by magnetic resonance imaging, providing Novartis with a broad efficacy package to take into regulatory discussions.

Twin Phase III victories give Novartis another potential pillar alongside the fast-growing Kesimpta franchise

REMODEL-1 and REMODEL-2 are identical randomized, double-blind Phase III studies comparing remibrutinib with teriflunomide in adults with relapsing multiple sclerosis. Around 2,000 patients participated globally, with treatment continuing for a flexible double-blind period of up to 30 months before patients can enter an open-label extension lasting as long as five years.

Annualized relapse rate served as the primary endpoint in both trials, and Novartis reported statistically significant superiority for remibrutinib versus teriflunomide in each study. Key secondary outcomes also favored remibrutinib, including reductions in new or enlarging T2 lesions and gadolinium-enhancing T1 lesions, suggesting that the drug affected both clinically observed relapses and inflammatory disease activity visible on brain imaging.

Disability progression could become another important component of the commercial argument, although those findings require more caution. A prespecified pooled analysis showed a positive trend for three-month confirmed disability progression and nominal statistical significance for six-month confirmed disability progression, but Novartis has not yet released the underlying hazard ratios or absolute event rates needed to assess the magnitude of that effect.

That distinction matters in a market where relapse reduction alone may not provide enough differentiation. Multiple sclerosis treatment has advanced substantially, and physicians can choose among oral medicines, injectable therapies and infused biologics capable of providing strong disease control, meaning new entrants increasingly need to demonstrate a compelling combination of efficacy, convenience and long-term safety.

Novartis already has a major commercial presence through Kesimpta, its monthly subcutaneous anti-CD20 therapy. Kesimpta sales increased 32% at constant currencies to $1.424 billion in the second quarter of 2026 and reached $2.588 billion during the first half, making it one of Novartis’ fastest-growing priority medicines.

Remibrutinib could expand rather than simply replace that franchise if its profile appeals to patients who prefer oral treatment. A successful launch would potentially give Novartis two differentiated high-efficacy options within relapsing multiple sclerosis, allowing physicians to choose between monthly subcutaneous B-cell depletion and daily oral BTK inhibition depending on individual treatment priorities.

Remibrutinib’s liver safety profile could become a major competitive factor in the BTK inhibitor race

Bruton’s tyrosine kinase inhibition has generated substantial interest in multiple sclerosis because BTK signaling influences both B cells and innate immune cells involved in neuroinflammation. Unlike therapies that mainly suppress peripheral immune activity, BTK inhibitors are being developed with the objective of influencing disease biology within the central nervous system as well.

The class has also encountered setbacks. Liver toxicity concerns have complicated development and regulatory review for certain competing BTK inhibitors, increasing attention on whether individual molecules can provide meaningful efficacy without introducing burdensome monitoring requirements or unacceptable hepatic risk.

Novartis reported that remibrutinib was well tolerated in REMODEL-1 and REMODEL-2 and produced no liver safety signal, including no cases meeting Hy’s Law criteria. The company said the findings were consistent with a broader clinical-development database involving more than 4,500 participants across multiple indications.

This does not establish that remibrutinib has a superior safety profile to competing BTK inhibitors because full adverse-event data and longer-term follow-up remain necessary. However, avoiding a meaningful liver signal in two large Phase III studies gives Novartis an important point of differentiation as regulators and physicians compare emerging therapies.

Roche is developing fenebrutinib, another oral BTK inhibitor that has produced strong Phase III results in relapsing multiple sclerosis, while Sanofi has advanced tolebrutinib across progressive forms of the disease. Remibrutinib therefore enters a competitive race rather than an open market, and its eventual position will depend heavily on the detailed relapse reduction, disability progression, magnetic resonance imaging results and safety profile disclosed at MSToronto2026.

The absence of numerical annualized relapse-rate data in the September 1 announcement is particularly important. Until Novartis releases those figures, it remains premature to determine whether remibrutinib can match or surpass the magnitude of benefit reported with other late-stage BTK inhibitors.

Existing Rhapsido approval could help Novartis turn remibrutinib into a broader multi-indication franchise

Remibrutinib already has regulatory and commercial validation outside multiple sclerosis. The medicine is marketed as Rhapsido for chronic spontaneous urticaria following United States approval in September 2025 and European approval in April 2026, giving Novartis manufacturing and commercial experience with the molecule before a potential neuroscience expansion.

Reuters reported that Rhapsido generated approximately $64 million in second-quarter sales, demonstrating that remibrutinib is beginning to contribute commercial revenue even before the much larger multiple sclerosis opportunity becomes available. Analysts cited by Reuters have estimated potential peak annual remibrutinib sales reaching several billion dollars across indications, although such forecasts depend on regulatory approvals, competitive positioning and uptake that remain uncertain.

The broader development program adds to that optionality. Novartis is studying remibrutinib in secondary progressive multiple sclerosis as well as immune-mediated conditions including hidradenitis suppurativa and food allergy, potentially allowing one molecule to participate across neuroscience, dermatology and immunology markets.

That multi-indication strategy could be especially valuable as Novartis manages the lifecycle of older blockbuster medicines. The company continues to generate strong growth from products including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio, but maintaining its longer-term earnings trajectory requires a steady sequence of new medicines capable of replacing revenue lost as mature products encounter generic or biosimilar competition.

Remibrutinib now looks considerably less speculative after two independently successful Phase III trials. Regulatory approval remains necessary, but the probability that the molecule becomes commercially relevant in multiple sclerosis has increased substantially following the REMODEL results.

Novartis stock rally signals investors see remibrutinib as more than an incremental pipeline win

Novartis shares rose sharply after the REMODEL announcement, climbing approximately 6% during September 1 trading even as broader European markets weakened. Reuters reported that Novartis gained 6.3% in European trading, while the company’s United States-listed shares also advanced strongly as investors digested the multiple sclerosis results.

The size of the move suggests the market viewed the readout as a meaningful reduction in pipeline risk rather than a routine late-stage success. Remibrutinib could add another significant growth asset to a company already benefiting from strong momentum across several priority medicines, while the potential for expansion across multiple indications increases its strategic value.

The reaction is particularly notable because Novartis is a pharmaceutical company with a market capitalization well above $200 billion, where an individual clinical-trial result normally needs substantial commercial implications to materially move the share price. Analysts cited in current market coverage have described remibrutinib as having multibillion-dollar sales potential, although estimates vary considerably and should not be treated as guaranteed outcomes.

Investor optimism should still be balanced against several unresolved issues. Novartis has not disclosed the exact relapse-rate reductions, disability progression was stronger on the six-month measure than the three-month measure, regulatory submissions have not yet occurred, and competitive BTK inhibitor programs could narrow the commercial opportunity by the time remibrutinib reaches the market.

The full MSToronto2026 presentation will therefore be unusually important for a trial that has already been declared successful. Detailed efficacy figures will allow investors and neurologists to compare remibrutinib more meaningfully with established multiple sclerosis therapies and competing BTK inhibitors, while complete safety data will show whether the favorable liver profile is accompanied by an otherwise competitive tolerability profile.

If those details support the topline message, Novartis could enter regulatory review with an oral treatment capable of extending its multiple sclerosis leadership rather than merely defending its existing franchise. The September 1 readout has removed one of the biggest clinical uncertainties surrounding remibrutinib, but differentiation and commercial execution will determine how much of its potential ultimately translates into revenue.

Key takeaways from Novartis’ remibrutinib Phase III wins and the expanding multiple sclerosis opportunity

• Remibrutinib met the primary annualized relapse-rate endpoint independently in both Phase III REMODEL studies.
• Novartis reported superiority over teriflunomide across all key secondary endpoints evaluated within each trial.
• The pivotal program also showed reductions in inflammatory brain lesions and encouraging signals for slowing disability progression.
• Novartis reported no liver safety signal and no cases meeting Hy’s Law criteria across the two studies.
• Detailed annualized relapse-rate reductions have not yet been disclosed, making the MSToronto2026 presentation critical for assessing competitive strength.
• Novartis plans global regulatory submissions for remibrutinib in relapsing multiple sclerosis following presentation of the full dataset.
• Kesimpta generated $1.424 billion in second-quarter sales, giving Novartis an established multiple sclerosis commercial platform that remibrutinib could complement.
• Remibrutinib is already marketed as Rhapsido for chronic spontaneous urticaria, reducing some molecule-level commercial and manufacturing uncertainty.
• Novartis shares rose roughly 6% as investors interpreted the dual Phase III success as a significant pipeline de-risking event.
• Remibrutinib’s ultimate commercial potential will depend on detailed efficacy, disability outcomes, long-term safety, regulatory decisions and competition from other BTK inhibitors.